Weedstocks Newswire Feed
Live Webcast Scheduled for September 12, 2018, 2:00pm EDT, followed by Q&A
TORONTO, Sept. 12, 2018 /CNW/ -- KHIRON LIFE SCIENCES CORP. ("Khiron" or the "Company") (TSXV: KHRN, OTCQB: KHRNF), a Canadian integrated medical cannabis company with core operations in Colombia, announced that Darren Collins, Chief Financial Officer, will present live at VirtualInvestorConferences.com on September 12, 2018. Individual and institutional investors, as well as advisors are invited to join the live webcast followed by a Q&A with Mr. Collins.
DATE: Wednesday, September 12, 2018 TIME: 2:00 PM EDT LINK: https://tinyurl.com/0912prepr
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/
WINNIPEG, Sept. 12, 2018 /CNW/ - DELTA 9 CANNABIS INC. (TSXV: NINE) ("Delta 9" or the "Company") announces that it granted today an aggregate of 3,000,000 stock options (the "Options") to certain directors, officers, employees and consultants of the Company in accordance with the Company's stock option plan.
"Our overall business and number of employees has grown in leaps and bounds since we listed our shares publicly last fall," said Delta 9 Chief Executive Officer John Arbuthnot. "We now have more than 120 full-time employees and continue to grow our workforce exponentially as we expand and look to execute on our business plan towards legalization of cannabis this fall.
"Stock options are an effective compensation tool for us to align employee and shareholder interests, to attract top talent, and for incentive and retention purposes."
Each Option is exercisable into one common share of the Company at a price of $1.79 per share for a period of five years from the date of grant. The Options will vest over twenty-four months, with one quarter (750,000 Options) vesting every six months from the date of grant.
Khiron announces closing of $12.93 million prospectus financing including full exercise of over-allotment option
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
TORONTO, Sept. 12, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia, is pleased to announce that it has closed today its previously announced best efforts short form prospectus offering of common shares ("Common Shares"), including the exercise in full of the over-allotment option (the "Offering").
A total of 14,375,000 Common Shares were sold at a price of $0.90 per Common Share (the "Issue Price") for aggregate gross proceeds of $12,937,500 (including the exercise in full of the over-allotment option). The Offering was completed by a syndicate of agents led by Canaccord Genuity Corp., and including GMP Securities L.P., Sprott Private Wealth LP, and Cormark Securities Inc. (together, the "Agents").
The net proceeds of the Offering are expected to be used by the Company to fund its facility expansion, equipment purchases, clinic construction, its cosmeceutical product line launch and general working capital purposes. The Offering is subject to TSX Venture Exchange ("TSXV") final acceptance of requisite regulatory filings.
In consideration for their services, the Agents received a cash commission equal to 7% of the gross proceeds of the Offering and compensation options (each a "Compensation Option") equal to 7% of the Common Shares sold pursuant to the Offering. Each Compensation Option is exercisable at the Issue Price into one Common Share for a period of 24 months from the date hereof.
HAMILTON, ON, Sept. 12, 2018 /CNW/ - Green Relief Inc., an ACMPR licensed producer of medical cannabis, is proud to announce that the company has entered into a joint venture agreement with a revolutionary tissue culturing company, launching March 2019.
GR Genetics, located in Grimsby, ON in a 32,000 sq. ft. facility, will enable Green Relief to continue its work with medical cannabis products through the tissue culturing of its own plants, while also conducting valuable industry research, strain research, strain modification and genetic improvement. Additionally, the company's physical location will act as a safe facility where genetic material will be stored and utilized for research purposes, with the goal of furthering Green Relief's plant genetics and strains. Upon its commencement, GR Genetics will be also be equipped to supply plants to ACMPR licensed producers across Canada, in addition to retail customers.
"One of the most important factors in delivering the highest-quality medical cannabis to our patients is knowing and owning our genetics," says Warren Bravo, CEO of Green Relief Inc. "With GR Genetics, we will have the opportunity to not only perform groundbreaking research and nurture a veritable library of strains with our own plant genetics, but we will also be in the unique position to provide plants to other ACMPR licensed producers across Canada as well as retail customers."
On August 23, 2018, Green Relief successfully acquired 63% interest in the joint venture, signaling a unique opportunity for tremendous growth regarding Green Relief's growing operations, with the ability to produce additional yield while eliminating the need for a physical nursery.
In addition to the growth of operations, genetic ownership, and research opportunities, Green Relief will be able to grow their cannabis products more efficiently. This will be accomplished utilizing a tissue culturing process to produce plantlets that are genetically identical to one another, removing the variation which can result from using mother plants.
B.C.-Based Sungrown Cannabis Producer Tantalus Labs Introduces Flagship Product Line and Opens to the Public
E-Commerce Membership Program Tantalus Prime to Offer Priority Access to Sungrown Cannabis and National Two Day Door-to-Door Delivery
VANCOUVER, Sept. 12, 2018 /CNW/ - B.C.-based cannabis producer, Tantalus Labs, has announced details of its inaugural product line, the Tantalus Range, and its e-commerce membership program, Tantalus Prime. Following the recent news of the company acquiring its Sales Licence, Tantalus Labs' highly-anticipated Sungrown cannabis products are now available for purchase by registered users at TantalusLabs.com
Tantalus Prime delivers elite B.C. grown cannabis directly to customers. The membership program provides express door-to-door delivery of cannabis products shipped straight from SunLab, Tantalus Labs' high efficiency greenhouse facility. With a simple registration process, Canadians from coast-to-coast can easily access some of the purest cannabis in the country, delivered right to their door.
"Establishing fast fulfillment of clean Sungrown cannabis to Canadians is the baseline of this membership program", said Dan Sutton, CEO of Tantalus Labs. "Members across the country can register for priority access to our products and benefit from legal express delivery of B.C cannabis."
A Tantalus Prime membership includes:
VANCOUVER, Sept. 12, 2018 /CNW/ - Namaste Technologies Inc. ("Namaste" or the "Company") (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company's wholly-owned subsidiary, Namaste Bahamas Inc. ("Namaste Bahamas"), has signed a distribution agreement (the "Distribution Agreement") with BlueSky Biologicals Inc. ("BlueSky"); a private British Columbia company; whereby Namaste Bahamas will distribute BlueSky's full-spectrum, hemp-derived cannabidiol ("CBD") products in its UK and European marketplace. The UK has classified CBD as a food supplement, as such, Namaste has been focused on building a carefully curated CBD supply chain for its UK platform. Namaste's launch of CBD sales in the UK and EU are the first steps of the Company's initiative to leverage its platform, technology and consumer databases to enter into cannabis consumable sales in the UK and EU.
In Canada, CBD is regulated under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") program, which restricts non-ACMPR vendors from selling it. CBD is a type of cannabinoid which is present in both cannabis and industrial hemp. Most CBD products outside of Canada are produced using industrial hemp, which is naturally high in CBD and low in delta-9 tetrahydrocannabinol ("THC").
The UK's recent classification of CBD opens the market to Namaste to leverage its site traffic and database to create a new high-growth revenue stream in its UK marketplace. BlueSky's full spectrum products have been created to fill the unmet global demand for cannabinoids. Their products have unique formulations and are based on their proprietary Golden Harvest™ cannabinoid blend-. Additionally, BlueSky's hemp is organically grown using sustainable farming practices, which is the foundation for their cannabinoid products containing no additives, chemicals, or preservatives.
The Company intends to develop a platform in the UK, subject to legalization of medical cannabis, which incorporates CBD and cannabis consumable sales in a similar platform to its Canadian subsidiary, Cannmart Inc. ("Cannmart" or "Cannmart.com"). Cannmart will be Canada's first medical cannabis "sales-only" license. Namaste will seek opportunities in the UK to leverage its database, its revolutionary telemedicine app, NamasteMD ("NamasteMD.com") and its cannabis journalling app, MyUppy Cannabis Journal ("MyUppy"), to introduce cannabis consumable products to the UK market, starting with CBD. The Company believes that as the industry evolves and cannabis becomes commoditized, its position as a global leader in cannabis e-commerce will secure Namaste's future in the global cannabis industry.
CSE: HUGE OTC: FSDDF FRA: 0K9
TORONTO, Sept. 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9), is pleased to report that on September 11, 2018 the Company traded an aggregate total of exactly 213,761,823 shares. FSD traded 143,260,988 Class B subordinate voting shares on the Canadian Securities Exchange ("CSE"), 1,888,500 on AQC-Lit, 15,369,000 on AQC-Neo, 241,740 on CXC, 5,309,399 on CX2, 6,473,592 on CXD, 22,500 on Lynx, 24,750,500 on Omega and 16,445,604 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 15.7% above the recorded all-time high of 184,718,114 also achieved by FSD on September 10, 2018, as confirmed by the CSE. This record is also 41% over the Company's previous reporting of achieving an all-time high of 151,183,895 on September 4, 2018.
The company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in yet another record-breaking achievement in the Canadian cannabis investment marketplace.
About FSD Pharma Inc.
FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour's drive from Toronto, FSD Pharma's management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.
KELOWNA, BC, Sept. 12, 2018 /CNW/ - Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) ("Marapharm" or the "Company") provides an update to shareholders on the status of permitting for final occupancy and continued cultivation in the temporary buildings.
Our contractor, Rafael Construction and Engineer, Pacific Design Concepts are "quarterbacking" their efforts to complete requirements as quickly as possible. Working with the City of North Las Vegas, Fire Department, and general contractors to conclude the final permitting necessary for our Certificates of Occupancy. Many of the city departments including Planning, Building Inspection and Fire have been extremely short staffed which have contributed to delays.
Kurt Keating, Director of Operations, reports: The existing vegetative plants are flourishing and vibrant. We are preparing our core genetics for propagation by increasing our plant count to meet our production cycle demands, in preparation for transitioning to the new buildings.
Over 100+ varieties of supplemental genetics in seed form have recently been added to our inventory. In addition to our core offerings, these supplemental genetics will be limited time offerings (LTO), seasonal offerings and special releases to keep pace with market demand and keep Marapharm ahead of the competition.
We're greatly anticipating our transition to full production. Our cultivation and compliance teams are building the future for Marapharm each day. Our objective is grand and achievable; we will focus on classic, award winning, and new varieties for the Vegas market all cultivated under certified organic protocol to ensure customer satisfaction and safety. Kurt Keating, Director of Operations.
TORONTO, Sept. 12, 2018 /CNW/ - The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (TSX:TGOD) (US:TGODF) is pleased to announce the launch of its premium, certified organic cannabis brand. This preeminent launch coincides with Canadian Organic Week, the largest annual celebration of organic food, farming and products across the country. This is a pivotal step for the Company in becoming the largest, organic cannabis brand in the world.
TGOD is proud to showcase its brand below.
Additional details of the launch will be provided in a subsequent press release.
TGOD cannabis adheres to the highest production standards for organic cultivation - the product is grown naturally in Canadian soil, without the use of synthetic pesticides, herbicides or fertilizers. According to a 2018 Hill & Knowlton research study, 57% of Canadian medical cannabis consumers and 43% of recreational cannabis consumers prefer organic cannabis. Of 116 licensed producers in Canada, TGOD is one of only two that are certified organic.
TGOD cannabis is never irradiated, resulting in rich and aromatic terpene profiles that are all natural. The Company's cannabis oils are derived using a super-critical CO2 extraction process that uses no harmful solvents or additives.
LEAMINGTON, ON, Sept. 12, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a wholesale supply agreement with Emblem Cannabis Corp., wholly owned subsidiary of Emblem Corp. and a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("Emblem") to supply 175,000 kg of high-quality cannabis over a five-year period starting May 2019 (the "Agreement") with a total of 25,000 kg deliverable for the balance of the first year. Under the terms of the Agreement, Aphria will receive a non-refundable deposit of $22.8 million, which is comprised of $12.8 million in cash, and 6,952,169 of common shares of Emblem. The Emblem common shares issued to Aphria are subject to a contractual lock-up and standstill arrangement, with five equal releases over the term of the Agreement, subject to certain customary exceptions.
Total Quantity (kg; in dried flower equivalent)
May 1st, 2019 – April 30th, 2020